Why the study?
Does intravenous cyclophosphamide improve cardiac dysfunction in lupus myocarditis?
Does intravenous cyclophosphamide improve cardiac dysfunction in lupus myocarditis?
Intravenous pulse cyclophosphamide may effectively reverse severe cardiac dysfunction in lupus myocarditis refractory to conventional therapy and oral corticosteroids.
Answers are grounded in this paper and cite their sources.
May support cyclophosphamide in refractory lupus myocarditis; hypothesis-generating and requires prospective confirmation before practice change.
We describe a Chinese woman who developed severe heart failure 3 years from the onset of systemic lupus erythematosus (SLE). Endomyocardial biopsy confirmed lupus myocarditis, with focal infiltrates of small lymphocytes and some polymorphic neutrophils. The conventional treatment for cardiac failure plus oral prednisolone failed to bring clinical and echocardiographical improvement until the addition of intravenous (i.v.) 'pulse' cyclophosphamide. Three weeks after i.v. cyclophosphamide treatment, there was significant improvement of her heart failure symptoms with improvement in the ejection fraction from 19% to 63%.
No takes yet. Share an insight, caveat, or question.
Chan et al. (2003) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: